Drugs / delolimogene mupadenorepvec
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04123470 | Jan 2020 → Jul 2023 | melanoma | Lokon Pharma AB | Completed | No outcome recorded |
| Phase 1/2 | NCT03555149 | Sep 2018 → Sep 2022 | colorectal cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT03225989 | Mar 2018 → Aug 2023 | bile duct carcinoma, colorectal cancer, ovarian cancer, pancreatic adenocarcinoma | Lokon Pharma AB | Completed | No outcome recorded |
| Phase 1/2 | NCT02705196 | Nov 2016 → Nov 2025 | malignant pancreatic neoplasm | Lokon Pharma AB | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | delolimogene mupadenorepvec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04123470 ↗ |
| Known as | LOAd703 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03225989 ↗ |
| Route | Other | “In this study, LOAd703 will be given by intratumoral injections.” NCT02705196 ↗ |